Cerbios-Pharma SA’s Post

Yet another issue of “Acquaint”, a market insight report for the month of Apr 24 is designed to provide a comprehensive overview of the pharmaceutical industry, all through the lens of PharmaTrac – Secondary Sales Audit is ready. For the month of Apr'24, the Indian Pharmaceutical Market (IPM) reported about 16413 Cr with a robust value growth of 9%. Varied performance is seen across therapeutic segments and new introductions performance. Read report for more insights. #IndianPharmaceuticals #PharmAnalytics #PharmInsights #IPM #Pharmarack

China has emerged as a significant player in the global generic drug active pharmaceutical ingredient (API) market. The country’s vast production capacity, low costs, and strategic location have made it an attractive destination for pharmaceutical companies seeking to source APIs. This article will delve into the role of China in the global generic drug API market, exploring its market share, production capacity, and the implications of its dominance. https://lnkd.in/ekvSBg3a

China has emerged as a significant player in the global generic drug active pharmaceutical ingredient (API) market. The country’s vast production capacity, low costs, and strategic location have made it an attractive destination for pharmaceutical companies seeking to source APIs. This article will delve into the role of China in the global generic drug API market, exploring its market share, production capacity, and the implications of its dominance. https://lnkd.in/eGbAifJx

- In May'24, the Indian Pharmaceutical Market (IPM) showcased robust 5.2% value growth, reaching a notable value of 16,712 Cr. - The overall growth of 5.2% for the month of May’24 is majorly contributed by Price rise and New introductions. Presenting the 12th edition of “Acquaint”, a market insight comprehensive report of the Indian pharmaceutical industry, all through the lens of PharmaTrac – Secondary Sales Audit #IndianPharmaceuticals #PharmAnalytics #PharmInsights #IPM #Pharmarack

useful summary

📣 Exciting news! Hichi Pharmaceutical's Iodixanol API has officially received market approval. This pivotal achievement will boost our market competitiveness and expand our role in the field of contrast agents. 🌟 Learn more: https://lnkd.in/gAnu4zZj #Pharmaceuticals #Iodixanol #ContrastAgents #MedicalInnovation #HichiPharma #MarketApproval 🌐

Building on my previous articles from December 2021 to July 2024 in CuttingEdge, the FDA issued an important update in September 2024 (Revision 2) regarding the 'Control of Nitrosamine Impurities in Human Drugs.' This new guidance replaces the February 2021 version and introduces key details on nitrosamine drug substance-related impurities (NDSRIs), their sources, and strategies for risk reduction. The updated guidance now categorizes two types of nitrosamine impurities: small-molecule nitrosamines and NDSRIs, the latter of which are structurally similar to the active pharmaceutical ingredient (API).

I am looking forward to being part of this distinguished panel at #ChemOutsourcing2024 to discuss the global nature of the pharmaceutical market space and how the regional needs are balanced against real-world pricing pressures that every drug company faces. Whether it is trying to achieve the best value in the Gx products that drive a huge portion of medicine today or the need for compressed development and clinical timelines that drive the innovator space - the global network of CDMO providers like Porton Pharma Solutions Ltd. play an ever increasing role.

Last week (June 24 to June 30), a total of 62 drug varieties were approved or deemed to have passed the equivalence evaluation. Among them, ApicHope's olmesartan medoxomil orally disintegrating tablets and CSPC Pharmaceutical Group's palbociclib tablets were the first domestically approved drugs of their kind. During the same period, 76 drug varieties were submitted for equivalence evaluation. According to the NMPA (National Medical Products Administration) website, ApicHope's olmesartan medoxomil orally disintegrating tablets and CSPC Pharmaceutical Group's palbociclib tablets both received their marketing approval on June 25. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical

Join us tomorrow for an insightful session on the Kenya National Pharmaceutical Policy #pharmaceuticalpolicy